MUC1-Tn is overexpressed in T-cell acute lymphoblastic leukemia (T-ALL) and serves as an effective target for CAR T cell therapy.
Linperlisib, a selective PI3Kδ inhibitor, enhances MUC1-Tn CAR T cell cytotoxicity and persistence both in vitro and in xenograft T-ALL models.
Linperlisib prevents CAR T cell exhaustion through suppression of the EGR1/DUSP2 signaling axis and promotes mitochondrial fusion and respiratory function.
This combination approach offers a promising strategy to overcome CAR T cell target-mediated fratricide and functional exhaustion in T-ALL treatment.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
